Ah, hidden right at the end inside the "about the studies":
> Both Danish studies show that the risk of developing NAION for the individual patient receiving treatment with Ozempic is only 0.2 per thousand per year, which is fortunately significantly lower than in the American study. NAION is a relatively rare condition, and the extra risk is therefore low. The researchers estimate that for every 10,000 people treated in a year, between 1.5 and 2.5 extra cases will be seen.
Sadly it's still relative, and they still leave you the mental maths to work out the natural frequencies.
> Both Danish studies show that the risk of developing NAION for the individual patient receiving treatment with Ozempic is only 0.2 per thousand per year, which is fortunately significantly lower than in the American study. NAION is a relatively rare condition, and the extra risk is therefore low. The researchers estimate that for every 10,000 people treated in a year, between 1.5 and 2.5 extra cases will be seen.
Sadly it's still relative, and they still leave you the mental maths to work out the natural frequencies.